Skip to main content

Remise en cause de la réalité d’une augmentation de la mortalité cardiovasculaire sous traitement par privation androgénique pour cancer de la prostate ?

Questioning the reality of an increase in cardiovascular mortality with androgen deprivation therapy for prostate cancer?

Références

  1. 1.

    Buvat J, Maggi M, Gooren L, et al (2010) Endocrine aspects of male sexual dysfunctions. J Sex Med 7:1627–1656

    PubMed  Article  Google Scholar 

  2. 2.

    Corona G, Rastrelli G, Monami M, et al (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165:1–18

    Article  Google Scholar 

  3. 3.

    Punnen S, Cooperberg MR, Sadetsky N, Carroll PR (2001) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29:3510–3516

    Article  Google Scholar 

  4. 4.

    Efstathiou JA, Bae K, Shipley WU, et al (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54:816–823

    PubMed  CAS  Article  Google Scholar 

  5. 5.

    Efstathiou JA, Bae K, Shipley WU, et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27:92–99

    PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Von Eckardstein A, Wu FCW (2004) Testosterone and cardiovascular diseases. In Nieschlag E, Behre HM (eds) Testosterone Action, Deficiency, Substitution. Cambridge University Press, Cambridge, pp 297–332

    Google Scholar 

  7. 7.

    McGrath KC, McRobb LS, Heather AK (2008) Androgen therapy and atherosclerotic cardiovascular disease. Vasc Health Risk Manag 4:11–21

    PubMed  CAS  PubMed Central  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to J. Buvat.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buvat, J. Remise en cause de la réalité d’une augmentation de la mortalité cardiovasculaire sous traitement par privation androgénique pour cancer de la prostate ?. Basic Clin. Androl. 21, 227–229 (2011). https://doi.org/10.1007/s12610-011-0152-1

Download citation